# Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT07686588** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Biying Chen** · enrollment: 20 (estimated)

## Conditions studied

- Recurrent or Metastatic Head and Neck Carcinoma

## Interventions

- **DRUG:** Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor

## Key facts

- **NCT ID:** NCT07686588
- **Lead sponsor:** Biying Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686588, "Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07686588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*